<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03661736</url>
  </required_header>
  <id_info>
    <org_study_id>17.09.CLI</org_study_id>
    <nct_id>NCT03661736</nct_id>
  </id_info>
  <brief_title>Growth of Infants With Cow's Milk Allergy Fed an Amino Acid-based Formula Containing Two Human Milk Oligosaccharides</brief_title>
  <acronym>PLATYPUS</acronym>
  <official_title>Growth of Infants With Cow's Milk Allergy Fed an Amino Acid-based Formula Containing Two Human Milk Oligosaccharides: Comparison With World Health Organization (WHO) Growth Standards in an Observational, Single-arm Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of this study is to provide longitudinal growth data in infants with
      moderate-to-severe cow's milk allergy fed an amino acid-based formula with two added human
      milk oligosaccharides.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The weight-for-age z-score (WAZ) compared with the WHO 2006 Child Growth Standard</measure>
    <time_frame>Comparison of baseline WAZ vs WAZ at 4 months</time_frame>
    <description>Weight gain will be measured in kg and converted to WAZ scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length-for-age Z-scores (LAZ) compared with the WHO 2006 Child Growth Standard</measure>
    <time_frame>1, 2, 3, 4 months from baseline and at 12 months of age</time_frame>
    <description>Body length will be measured in cm and converted to LAZ scores</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Head circumference (HCAZ) compared with the WHO 2006 Child Growth Standard</measure>
    <time_frame>1, 2, 3, 4 months from baseline and at 12 months of age</time_frame>
    <description>Head circumference will be measured in cm converted to HCAZ scores</description>
  </other_outcome>
  <other_outcome>
    <measure>Monitoring of CMPA-related symptoms</measure>
    <time_frame>1, 2, 3 and 4 months from baseline and at 12 months of age</time_frame>
    <description>CMPA-related symptoms will be documented by the study physician on data collection forms</description>
  </other_outcome>
  <other_outcome>
    <measure>Faecal microbial composition</measure>
    <time_frame>Enrolment,1, 2, 3 and 4 months from treatment start and also at 12 months of age</time_frame>
    <description>Faecal samples will be collected before and after the study formula ingestion</description>
  </other_outcome>
  <other_outcome>
    <measure>Product compliance</measure>
    <time_frame>1, 2, 3 and 4 months from baseline and at 12 months of age</time_frame>
    <description>Daily quantity consumed (mL) will be recorded for the 3 days preceding each visit in a diary given to the parent or caregiver</description>
  </other_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cow Milk Allergy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Food for Specific Medical Purpose</intervention_name>
    <description>Infants aged 1 to 8 months with moderate-to-severe cow's milk allergy fed an amino acid-based formula with two added human milk oligosaccharides</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Full-term infants 1-8 months of age with symptoms suggestive of moderate-to-severe CMPA who
        have failed a trial of extensively hydrolyzed formula (EHF) of at least 2 weeks or who
        require amino acid formula as first line of treatment
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Full term infant (37 weeks ≤ gestation ≤ 42 weeks)

          2. 2500g ≤ birth weight ≤ 4500g

          3. Having obtained written informed consent form the infant's parents or legally
             authorized representatives (LAR).

          4. Infant aged between 1 and 8 months.

          5. Exclusively formula-fed at time of enrolment; or CMPA infant receiving partial
             breastfeeding and infant's mother having independently elected before enrolment to
             exclusively formula feed.

          6. Infants with physician-diagnosed CMPA as per standard clinical practice:

        Exclusion Criteria:

          1. Previous treatment with AAF &gt; 72 hours

          2. Known underlying medical condition that would impair growth (as per physician's
             assessment, e.g. unstable congenital heart disease, cystic fibrosis, metabolic
             disorder, chronic liver disease etc.)

          3. Demonstrated chronic malabsorption which is not due to CMPA.

          4. Other significant pre-natal and/or serious post-natal disease other than CMPA before
             enrolment (per investigator's medical decision).

          5. Infants whose parents or caregivers who cannot give informed consent or who cannot be
             expected to comply with study procedures.

          6. Treatment with systemic corticosteroids (oral or intravenous) for &gt;72 hours within 4
             weeks before enrolment (topical corticosteroids allowed)

          7. Infants taking probiotic preparations for &gt; 72 hour within 4 weeks before enrolment

          8. Currently participating or having participated in another clinical trial since birth.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>8 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Monika Tadi, PhD</last_name>
    <phone>0041219244100</phone>
    <email>monika.tadi@nestle.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Children's Hospital at Westmead</name>
      <address>
        <city>Sydney</city>
        <state>Westmead</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dianne Campbell</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Milk Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

